Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Stephen Bloch sold 318,893 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $50.23, for a total value of $16,017,995.39. Following the completion of the transaction, the director owned 1,870,042 shares in the company, valued at $93,932,209.66. This represents a 14.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Liquidia Price Performance
LQDA opened at $56.93 on Friday. The stock has a 50-day moving average price of $39.70 and a 200-day moving average price of $35.94. Liquidia Corporation has a 12-month low of $11.85 and a 12-month high of $59.75. The company has a current ratio of 2.22, a quick ratio of 1.84 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $5.06 billion, a P/E ratio of 406.67 and a beta of 0.41.
Liquidia (NASDAQ:LQDA – Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia’s revenue was up 4187.1% compared to the same quarter last year. Equities analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Stock Report on Liquidia
Institutional Investors Weigh In On Liquidia
Several institutional investors have recently bought and sold shares of LQDA. Farallon Capital Management LLC grew its position in shares of Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares during the last quarter. TCG Crossover Management LLC bought a new stake in shares of Liquidia in the 3rd quarter worth approximately $38,887,000. Caprock Group LLC bought a new stake in shares of Liquidia in the 3rd quarter worth approximately $37,114,000. MPM Bioimpact LLC grew its position in shares of Liquidia by 600.4% in the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after buying an additional 1,200,869 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in shares of Liquidia in the 3rd quarter worth approximately $12,571,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.
Liquidia News Roundup
Here are the key news stories impacting Liquidia this week:
- Positive Sentiment: Liquidia’s first-quarter results beat Wall Street expectations on both earnings and revenue, reinforcing confidence that YUTREPIA is gaining commercial traction and that profitability is improving. Results: Liquidia Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts
- Positive Sentiment: Several analysts raised estimates and price targets after the earnings report, including HC Wainwright boosting near-term EPS forecasts and keeping a Buy rating with a $67 target, which supports the bullish outlook on LQDA. Liquidia (LQDA) price target increased by 22.37% to 63.24
- Positive Sentiment: Valuation-focused commentary highlighted that YUTREPIA-driven profitability and strong first-quarter performance could justify Liquidia’s recent share price strength if launch momentum continues. A Look At Liquidia (LQDA) Valuation After YUTREPIA Fueled Profitability And Strong First Quarter Results
- Positive Sentiment: Zacks noted improving earnings estimate revisions, suggesting analysts see additional upside potential for Liquidia in the near term. Earnings Estimates Moving Higher for Liquidia Corporation (LQDA): Time to Buy?
- Neutral Sentiment: Director Stephen Bloch sold 318,893 shares, a notable insider transaction, but it does not necessarily signal a change in the company’s operating outlook. Stephen Bloch Sells 318,893 Shares of Liquidia (NASDAQ:LQDA) Stock
- Neutral Sentiment: One analyst lowered a longer-dated EPS estimate, showing there is still some disagreement on how quickly growth can scale over time. Liquidia stock and analyst reports
About Liquidia
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Featured Articles
- Five stocks we like better than Liquidia
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
